---

Congenital Hyperbilirubinemia: Causes, Mechanisms & Syndromes

---

Bilirubin Metabolism — Brief Overview

---

Classification

---

UNCONJUGATED HYPERBILIRUBINEMIA SYNDROMES

1. Gilbert Syndrome

• Most common inherited cause; affects 3–12% of the population (male predominance 1.5–7:1)
• Gene: Promoter region polymorphism in UGT1A1 (TA repeat insertion: UGT1A1*28) → reduced transcription factor binding → UGT1A1 activity reduced to 10–33% of normal
• Inheritance: Autosomal recessive (some classify as complex haplotype trait)
• Bilirubin: Mild unconjugated hyperbilirubinemia, usually < 4–6 mg/dL, fluctuates
• Triggers: Fasting, stress, alcohol, concurrent illness, exercise
• Clinical: Essentially harmless — no liver damage, no kernicterus risk; may actually be cardioprotective and anti-inflammatory due to bilirubin's antioxidant properties
• Labs: All liver function tests otherwise normal
• Treatment: None required

---

2. Crigler-Najjar Syndrome Type I

• Gene: Complete loss-of-function mutations (nonsense, frameshift) in UGT1A1 → total absence of bilirubin UDP-glucuronosyltransferase activity
• Inheritance: Autosomal recessive
• Bilirubin: Severely elevated unconjugated bilirubin > 20 mg/dL (often 18–45 mg/dL)
• Clinical:
  • Severe neonatal jaundice
  • Kernicterus (bilirubin encephalopathy) — bilirubin crosses the blood-brain barrier (only unconjugated can) → brain damage, mental retardation
  • Frequently fatal within the first 15 months of life without treatment
• Treatment:
  • Phototherapy 10–12 hours/day (blue light converts bilirubin to a water-soluble isomer excreted in urine)
  • Phenobarbital has NO effect (no UGT1A1 activity to induce)
  • Liver transplantation is the definitive cure

---

3. Crigler-Najjar Syndrome Type II (Arias Syndrome)

• Gene: Nonsynonymous point mutations in UGT1A1 → residual activity ≤ 10% of normal (not total absence)
• Inheritance: Autosomal recessive
• Bilirubin: Elevated but usually < 20 mg/dL (range 6–25 mg/dL)
• Clinical:
  • More benign than Type I; patients survive into adulthood
  • Kernicterus is rare but can occur under metabolic stress (illness, surgery)
  • Mild or no neurological impairment under normal conditions
• Treatment:
  • Phenobarbital induces residual UGT1A1, reducing bilirubin by up to 75%
  • Phototherapy if needed

---

Spectrum Summary: UGT1A1 Disorders

---

CONJUGATED HYPERBILIRUBINEMIA SYNDROMES

4. Dubin-Johnson Syndrome

• Gene: Mutations in ABCC2 (encoding MRP2, multidrug resistance-associated protein 2) → impaired canalicular secretion of conjugated bilirubin into bile
• Inheritance: Autosomal recessive
• Bilirubin: Conjugated (direct) hyperbilirubinemia, typically 2–5 mg/dL (~60% direct-reacting); can worsen with estrogens (oral contraceptives), pregnancy, or infections
• Clinical:
  • Asymptomatic jaundice, often intermittent
  • Occasional hepatosplenomegaly
  • Hallmark: Liver appears grossly black due to deposition of dark melanin-like pigment in hepatocytes (centrilobular dark pigment on biopsy)
  • All other liver function tests are normal
• Diagnosis:
  • Urine coproporphyrin: total is normal, but isomer I constitutes > 80% of total (normally coproporphyrin III predominates at ~75%)
  • Liver biopsy shows characteristic dark pigment
• Prognosis: Benign; no progressive liver damage

---

5. Rotor Syndrome

• Gene: Simultaneous mutations in both SLCO1B1 and SLCO1B3 (encoding OATP1B1 and OATP1B3) → impaired reuptake of bilirubin conjugates from the sinusoid back into hepatocytes (i.e., bilirubin conjugates that re-enter the circulation cannot be recaptured)
• Inheritance: Autosomal recessive
• Bilirubin: Conjugated hyperbilirubinemia, 3–7 mg/dL (occasionally up to 20 mg/dL); ~60% direct-reacting
• Clinical:
  • Asymptomatic jaundice
  • Liver biopsy is completely normal (no pigment — this distinguishes it from Dubin-Johnson)
  • All other liver function tests are normal
• Diagnosis:
  • Urine coproporphyrin: total is elevated 2–5 fold (vs. Dubin-Johnson where total is normal); coproporphyrin I < 80% of total
• Distinction from Dubin-Johnson: Rotor = elevated total coproporphyrin; Dubin-Johnson = normal total but abnormal ratio

---

FAMILIAL INTRAHEPATIC CHOLESTASIS SYNDROMES

6. Progressive Familial Intrahepatic Cholestasis (PFIC)

• PFIC-1 and PFIC-2 are associated with low GGT (distinguishing from most other cholestatic diseases)
• PFIC-2 carries the highest risk of malignancy — surveillance is mandatory
• Benign Recurrent Intrahepatic Cholestasis (BRIC) shares mutations with PFIC-1 (ATP8B1) and PFIC-2 (ABCB11) but presents with intermittent reversible episodes rather than progressive disease

---

NEONATAL / PHYSIOLOGIC (Non-inherited but Developmental)

7. Neonatal Physiologic Jaundice

• UGT1A1 levels are low at birth, reaching adult levels only by 3–4 months of age
• Accelerated hemolysis of fetal hemoglobin further increases bilirubin load
• Transient unconjugated hyperbilirubinemia nearly universal in the first week of life
• Breastfeeding can exacerbate it (bilirubin-deconjugating enzymes in breast milk; progestational steroids inhibit UGT1A1)
• Treatment: Blue-light phototherapy (converts bilirubin to water-soluble photoisomers); phenobarbital if needed
• Kernicterus risk if unconjugated bilirubin > 20–25 mg/dL (exceeds albumin binding capacity)

---

Key Differentiating Points

---

---

Bartter Syndrome

The clinical picture closely mimics chronic loop diuretic (furosemide) use.

---

Anatomy & Physiology of the TAL (Key to Understanding Bartter)

1. NKCC2 (apical) co-transports Na⁺, K⁺, and 2Cl⁻ into the cell
2. ROMK (apical K⁺ channel) recycles K⁺ back into the lumen — this creates a lumen-positive transepithelial voltage
3. This voltage drives paracellular Ca²⁺ and Mg²⁺ reabsorption
4. Cl⁻ exits basolaterally via CLC-Kb chloride channels, which require the Barttin (BSND) subunit
5. The Na⁺/K⁺-ATPase maintains the gradient

---

Genetic Classification (Types 1–5)

Inheritance: All types are autosomal recessive, except BS5 which involves an activating (gain-of-function) dominant mutation in CaSR.

---

Pathophysiology: The Chain of Events

Loss of NaCl reabsorption in TAL
        ↓
↓ NaCl delivery to macula densa
        ↓
Impaired tubuloglomerular feedback (TGF)
        ↓
↑ COX-2 activity in TAL & macula densa
        ↓
↑ Prostaglandin E₂ (PGE₂)
        ↓
↑ Renin → ↑ Angiotensin II → ↑ Aldosterone (hyperreninemic hyperaldosteronism)
        ↓                                     ↓
Afferent arteriolar dilation          ↑ Na⁺ reabsorption in collecting duct
(vascular resistance to ANG II)       ↑ K⁺ secretion → Hypokalemia
                                       ↑ H⁺ secretion → Metabolic alkalosis

• Juxtaglomerular apparatus hypertrophy (due to chronic renin hyperstimulation)
• Vascular unresponsiveness to angiotensin II → persistent normotension or hypotension despite high aldosterone
• Loss of lumen-positive voltage in TAL (Types 1 & 2) → hypercalciuria + nephrocalcinosis

---

Clinical Presentations

Antenatal / Neonatal Bartter (Types 1, 2, 4)

• Maternal polyhydramnios (fetal polyuria) → premature birth
• Postnatal: polyuria, polydipsia, vomiting, failure to thrive
• Hypercalciuria → nephrocalcinosis
• Marked electrolyte wasting (hypokalemia, hyponatremia, hypochloremia)
• Elevated plasma renin, aldosterone, and PGE₂
• Type 2 special feature: Neonates initially present with hyperkalemia and hyponatremia (mimicking pseudohypoaldosteronism type 1), because ROMK also mediates K⁺ secretion in the collecting duct; this resolves after a few weeks as alternative K⁺ channels compensate

Classic Bartter (Type 3 — CLCNKB)

• Onset: first decade of life (occasionally adolescence or adulthood)
• Symptoms: vomiting, polyuria, recurrent dehydration, muscle cramps, weakness
• Hypomagnesemia frequent (CLC-Kb expressed in both TAL and DCT)
• Can phenotypically overlap with Gitelman syndrome (some patients look like Gitelman)
• Electrolyte disturbances can be paradoxically more severe than antenatal forms

Bartter with Deafness (Type 4 — Barttin)

• Severe form of BS3 + sensorineural deafness (Barttin required for inner ear CLC-Ka/Kb function)
• Progressive CKD is common
• Barttin loss = functional loss of both CLC-Ka and CLC-Kb

---

Biochemical Profile

---

Differential Diagnosis

Key rule: Low blood pressure + high urine Cl⁻ + high renin + hypokalemic alkalosis = Bartter or Gitelman. Distinguish by urine Ca²⁺ and Mg²⁺.

---

Treatment

Acute (Neonates/Severe Episodes)

• IV saline for fluid and electrolyte correction
• Potassium chloride supplementation (oral or IV)
• Monitor closely — supplementation causes transient rise then urinary loss; smaller, more frequent doses are safer

Chronic / Maintenance

ACE inhibitors are generally not recommended in antenatal/severe forms due to hypotension risk.

---

Outcomes

• With appropriate therapy, most patients clinically improve significantly
• Progressive CKD is a concern, especially in Type 4 (Barttin mutations)
• Antenatal forms carry risk of extreme prematurity complications (intracranial hemorrhage, bronchopulmonary dysplasia)
• Severe hypokalemia can cause arrhythmias, paralysis, rhabdomyolysis, apnea
• Some patients diagnosed incidentally in adulthood with mild phenotypes

---